[go: up one dir, main page]

WO2025111553A3 - Composition de lamp-1 humaine à base d'anticorps et ses utilisations - Google Patents

Composition de lamp-1 humaine à base d'anticorps et ses utilisations Download PDF

Info

Publication number
WO2025111553A3
WO2025111553A3 PCT/US2024/057108 US2024057108W WO2025111553A3 WO 2025111553 A3 WO2025111553 A3 WO 2025111553A3 US 2024057108 W US2024057108 W US 2024057108W WO 2025111553 A3 WO2025111553 A3 WO 2025111553A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
composition
polypeptides
based human
human lamp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/057108
Other languages
English (en)
Other versions
WO2025111553A2 (fr
WO2025111553A8 (fr
Inventor
Umar Mahmood
Lital BEN NAM
Pedram HEIDARI
Bahar ATAEINIA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of WO2025111553A2 publication Critical patent/WO2025111553A2/fr
Publication of WO2025111553A3 publication Critical patent/WO2025111553A3/fr
Publication of WO2025111553A8 publication Critical patent/WO2025111553A8/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1063—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from stomach or intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des polypeptides, tels que des anticorps, des nanocorps et des fragments de liaison à l'antigène de ceux-ci, et l'utilisation de ces polypeptides pour marquer la LAMP-1 de surface cellulaire. Les polypeptides de l'invention peuvent être utilisés pour marquer et suivre des cellules tumorales dans des études d'imagerie, ainsi que pour traiter une grande diversité de cancers et de maladies inflammatoires.
PCT/US2024/057108 2023-11-22 2024-11-22 Composition de lamp-1 humaine à base d'anticorps et ses utilisations Pending WO2025111553A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202363602198P 2023-11-22 2023-11-22
US63/602,198 2023-11-22
US202463549177P 2024-02-02 2024-02-02
US63/549,177 2024-02-02

Publications (3)

Publication Number Publication Date
WO2025111553A2 WO2025111553A2 (fr) 2025-05-30
WO2025111553A3 true WO2025111553A3 (fr) 2025-06-26
WO2025111553A8 WO2025111553A8 (fr) 2025-07-24

Family

ID=95827553

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/057108 Pending WO2025111553A2 (fr) 2023-11-22 2024-11-22 Composition de lamp-1 humaine à base d'anticorps et ses utilisations

Country Status (1)

Country Link
WO (1) WO2025111553A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130137856A1 (en) * 2010-07-16 2013-05-30 Jan Steyaert Protein binding domains stabilizing functional conformational states of gpcrs and uses thereof
US20180030120A1 (en) * 2015-02-04 2018-02-01 Abcelex Technologies Inc. Anti-salmonella antibodies and uses thereof
US20180142032A1 (en) * 2012-12-27 2018-05-24 Sanofi Anti-lamp1 antibodies and antibody drug conjugates, and uses thereof
WO2023034571A1 (fr) * 2021-09-03 2023-03-09 Go Therapeutics, Inc. Anticorps anti-glyco-lamp1 et leurs utilisations

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130137856A1 (en) * 2010-07-16 2013-05-30 Jan Steyaert Protein binding domains stabilizing functional conformational states of gpcrs and uses thereof
US20180142032A1 (en) * 2012-12-27 2018-05-24 Sanofi Anti-lamp1 antibodies and antibody drug conjugates, and uses thereof
US20180030120A1 (en) * 2015-02-04 2018-02-01 Abcelex Technologies Inc. Anti-salmonella antibodies and uses thereof
WO2023034571A1 (fr) * 2021-09-03 2023-03-09 Go Therapeutics, Inc. Anticorps anti-glyco-lamp1 et leurs utilisations

Also Published As

Publication number Publication date
WO2025111553A2 (fr) 2025-05-30
WO2025111553A8 (fr) 2025-07-24

Similar Documents

Publication Publication Date Title
EP4512478A3 (fr) Traitement du cancer
DE60039448D1 (de) Gegen das prostata-stammzellantigen (psca) gerichtete antikörper und deren verwendung
CY1122627T1 (el) Αντισωματα εναντι της ceacam6 και χρησεις αυτων
DE602006021296D1 (de) Monoklonale antikörper und einzelkettenantikörper fragments gegen das zelloberflächen prostataspezifische membranantigen
WO2007038637A3 (fr) Anticorps monoclonaux humains diriges contre cd70
MX2009013824A (es) Proteinas de enlace de antigeno que enlazan par-2.
EA200801509A1 (ru) Человеческие моноклональные антитела к протеинтирозинкиназе 7 ( ptk7) и способы применения антител против ptk7
MX2009006277A (es) Anticuerpos humanos que se enlazan a cd70 y usos de los mismos.
MY150246A (en) Alpha 5 - beta 1 antibodies and their uses
DE60239454D1 (de) Rekombinanter, tumorspezifischer antikörper und dessen verwendung
WO2006089230A3 (fr) Anticorps monoclonaux humains diriges contre l'antigene d'enveloppe specifique de la prostate
CY1118714T1 (el) Υψηλης συγγενειας ανθρωπινα αντισωματα κατα του ανθρωπινου ενεργοποιουμενου απο πρωτεαση υποδοχεα-2
WO2003048328A3 (fr) Anticorps contre l'antigene tumoral de l'anhydrase carbonique ix (ca ix)
MX2009009450A (es) Anticuerpos monoclonales para he4 y metodos para su uso.
MY162559A (en) Human anti-il-23 antibodies, compositions, methods and uses
WO2006076691A3 (fr) Anticorps 2 associes a la translocation de recepteur immunitaire (irta-2) et leurs utilisations
WO2008136848A3 (fr) Nouveaux anticorps anti-notch3 et leur utilisation dans la détection et le diagnostic d'une maladie
WO2005097185A3 (fr) Anticorps irta-5 et utilisations de ces derniers
EA200970884A1 (ru) Способы лечения рака путем введения комбинаций человеческого интерлейкина ил-18
DK1841793T3 (da) Ovr110-antistofsammensætninger og fremgangsmåder til anvendelse deraf
WO2024086617A3 (fr) Anticorps anti-cd3 dépendant du ph et procédés associés
WO2007016590A3 (fr) Compositions d'anticorps ovr232v3 et procedes d'utilisation
WO2006053110A3 (fr) Compositions d'anticorps anti-ovr110 et methodes d'utilisation correspondantes
WO2002053700A3 (fr) Molecules isolees renfermant des epitopes a fractions sulfatees, anticorps vis-a-vis de ces epitopes, et utilisations correspondantes
WO2003066663A3 (fr) Peptides utilises pour reconnaitre et cibler des tumeurs de cellules gliales